Skip to main content

Advertisement

SpringerLink
Log in

Low-dose methotrexate-induced pancytopenia

  • Brief Report
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Methotrexate (MTX) has gained wide acceptance among both patients and rheumatologists due to its efficacy and safe therapeutic window in a variety of inflammatory rheumatological disorders. However, it has the potential to cause serious, life-threatening complications and even mortality. In the present series, we have reviewed our data of five patients who developed serious pancytopenia after the use of MTX, including one who died. Two of these resulted from prescription errors by primary care physicians. The clinical, laboratory, and outcome profile of all five cases are discussed with a brief review of the literature about MTX-induced pancytopenia. There is an urgent need to increase awareness in primary care physicians, patients, and pharmacists toward informed prescribing, dispensing, and monitoring of MTX to prevent such mishaps in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. McKendry RJ (1997) The remarkable spectrum of methotrexate toxicities. Rheum Dis Clin North Am 23:939–954

    Article  PubMed  CAS  Google Scholar 

  2. Gutierrez-Urena S, Molina JF, Garcia CO, Cuellar ML, Espinoza LR (1996) Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum 39:272–276

    Article  PubMed  CAS  Google Scholar 

  3. Kuitunen T, Malmstrom J, Palva E, Pettersson T (2005) Pancytopenia induced by low-dose methotrexate. A study of the cases reported to the Finnish Adverse Drug Reaction Register from 1991 to 1999. Scand J Rheumatol 34:238–241

    Article  PubMed  CAS  Google Scholar 

  4. Lim AY, Gaffney K, Scott DG (2005) Methotrexate-induced pancytopenia: serious and under-reported? Our experience of 25 cases in 5 years. Rheumatology (Oxford) 44:1051–1055

    Article  CAS  Google Scholar 

  5. Chan J, Sanders DC, Du L, Pillans PI (2004) Leflunomide-associated pancytopenia with or without methotrexate. Ann Pharmacother 38:1206–1211

    Article  PubMed  Google Scholar 

  6. Sosin M, Handa S (2003) Low dose methotrexate and bone marrow suppression. BMJ 326:266–267

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

    Yogesh Preet Singh, Amita Aggarwal, Ramnath Misra & Vikas Agarwal

Authors
  1. Yogesh Preet Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amita Aggarwal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ramnath Misra
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Vikas Agarwal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vikas Agarwal.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Preet Singh, Y., Aggarwal, A., Misra, R. et al. Low-dose methotrexate-induced pancytopenia. Clin Rheumatol 26, 84–87 (2007). https://doi.org/10.1007/s10067-006-0301-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-006-0301-7

Keywords

Search

Navigation